Skip Navigation



Annals of Oncology Advance Access published online on July 23, 2009
Annals of Oncology, doi:10.1093/annonc/mdp296
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
21/2/223    most recent
mdp296v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Donnem, T.
Right arrow Articles by Bremnes, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Donnem, T.
Right arrow Articles by Bremnes, R. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer

T. Donnem1,2,*, S. Al-Saad3,4, K. Al-Shibli3,5, L.-T. Busund3,4 and R. M. Bremnes1,2

1 Department of Oncology, Institute of Clinical Medicine, University of Tromso, Tromso
2 Department of Oncology, University Hospital of Northern Norway, Tromso
3 Institute of Medical Biology, University of Tromso, Tromso
4 Department of Pathology, University Hospital of Northern Norway, Tromso
5 Department of Pathology, Nordland Central Hospital, Bodo, Norway

* Correspondence to: Dr T. Donnem, Department of Oncology, Institute of Clinical Medicine, University of Tromso, 9037 Tromso, Norway. Tel: +47-77626000; Fax: +47-77626779; E-mail: tom.donnem{at}uit.no

Background: Platelet-derived growth factors (PDGFs) and vascular endothelial growth factors and their receptors [platelet-derived growth factor receptors (PDGFRs) and vascular endothelial growth factor receptors (VEGFRs)] are related to both angiogenesis and lymphangiogenesis and are important targets in new cancer treatment strategies. We aimed to study the PDGFs/PDGFRs and correlations with lymph node metastasis (LNM) and investigate the prognostic impact of the co-expression of PDGF-B and VEGFR-3 and its correlation with LNM.

Patients and methods: Tumor tissue samples from 335 resected patients with stage I–IIIA non-small-cell lung cancer (NSCLC) were obtained and tissue microarrays were constructed from duplicate cores of tumor cells and tumor-related stroma from each specimen. Immunohistochemistry was used to evaluate the expression of the molecular markers PDGF-A, PDGF-B, PDGF-C, PDGF-D, PDGFR-{alpha}, PDGFR-β, VEGFR-3 and D2-40.

Results: There were 232 N0 and 103 N+ patients (76 N1 and 27 N2). In multivariate analyses, high tumor cell PDGF-A expression (P = 0.017) correlated with LNM. Tumor cell co-expression of VEGFR-3 and PDGF-B correlated with nodal metastasis and was an independent indicator of poor prognosis (hazard ratio 4.8, confidence interval 95% 2.80–8.31, P < 0.001).

Conclusion: Tumor cell PDGF-A expression correlates with LNM, and the co-expression of PDGF-B and VEGFR-3 is strongly associated with poor survival in NSCLC patients.

angiogenesis, lymphangiogenesis, NSCLC, PDGFs, VEGFR-3

Received for publication October 16, 2008. Revision received January 11, 2009. Accepted for publication April 27, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.